Abstract: The invention relates to the area of the chemical-pharmaceutical industry and medicine, in particular, to an agent for treatment of dependence on ethyl alcohol and/or drugs, treatment of psychosomatic and neurological complications in such patients; to pharmaceutical compositions containing this agent; and to treatment methods for psychosomatic and neurological complications with this agent. The aim of the invention is to develop a new pharmaceutical agent with minimal side effects. The proposed therapeutic substance, for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in such patients, which is presented by polyprenols of formula (1) where n=8-20. Therapeutic composition for treatment of addiction to ethanol and/or drugs, for treatment of psychosomatic and neurological complications in patients is suggested, which includes an effective amount of polyprenols of formula (1) where n=8-20.

Abstract: The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.

Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a corticosteroid and exosomes. By means of the combination therapy diseases such as osteoarthritis, arthritis and/or degenerative spinal diseases can be treated.

Abstract: A long-lasting, controlled-release local anesthetic liposome preparation is produced by: providing a liposome composition, which is obtained by mixing, in a water-miscible organic solvent, a first aqueous phase solution with a water-miscible organic solution, in which a phospholipid and cholesterol are contained at a defined total concentration, at a defined ratio by volume thereby obtaining an emulsion wherein a total concentration of the phospholipid and cholesterol in the mixed phase is at 15 w/v % to 50 w/v %, followed by subjecting the emulsion to external solution exchange with a second aqueous phase solution to obtain a liposome composition wherein an ion gradient is formed between an internal-region aqueous phase of a liposome membrane made of the first aqueous phase solution and an external-region aqueous phase of the liposome membrane made of the second aqueous phase solution; and encapsulating a local anesthetic in the internal-region aqueous phase according to a remote loading method.

Abstract: An oral care composition comprising a diluted sodium calcium alginate gel, wherein the oral care composition is a toothpaste, a gel, a mouthwash or a mouthrinse.

Abstract: Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.

Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, GAMMAGARD LIQUID (an immune globulin infusion (human)); ADVATE (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, (rAHF)); BAX 111 (vonicog alfa, or [618-threonine,709-aspartic acid] von Willebrand factor Homo sapiens (1381A>T,1472H>D variant)); or an adeno-associated viral vector containing a liver-specific human factor IX expression cassette, e.g., sscAAV2/8-LP1-hFIXco.

Abstract: An animal, bird, and repellent formulation and method for warding off deer, geese, birds and insects from shrubs, grass, water, walks, parking lots in around buildings and the like. The formulation is a mixture of water, rosemary oil, mint oil, cedar oil, kaolin clay, a thickener, preservative, white distilled vinegar and dried eggs. This formulation can be applied to a support medium, such as crushed eggshells, nutshells, or corncobs and then disbursed over the surface to be protected. The mixture can also be formed into a viscous composition and sprayed over the area. Additionally, this mixture can be applied to stagnate water to kill mosquito larvae or on a variety of surfaces to repel insects such as flies, spiders, beetles, ants and so forth.

Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

Abstract: The present invention is based, in part, upon the discovery of charged lipids that provide advantages when used in lipid particles for the in vivo delivery of a therapeutic agent. As such, described herein are compounds useful for delivering a nucleic acid to a cell.

Abstract: It is intended to provide a liquid oral composition and a liquid food composition in which calcium phosphate such as hydroxyapatite or tricalcium phosphate can be stably dispersed and prevented from being precipitated or separated out even in long-term storage. Calcium phosphate mixed with xanthan gum and polyglycerin fatty acid ester can be stably dispersed even in long-term storage and prevented from being precipitated or separated out even when used in liquid oral compositions such as mouthwashes, liquid dentifrices, and oral detergents or in liquid food compositions such as milk, soy milk, yoghurt, and refreshing beverages. In addition, calcium phosphate mixed with xanthan gum and polyglycerin fatty acid ester further supplemented with an amphoteric surfactant can be more effectively prevented from being precipitated or separated out in liquid oral compositions such as mouthwashes, liquid dentifrices, and oral detergents.

Abstract: The invention relates to a chewable object for carnivorous pets. The inventive object (1) is provided with an elongated shape and comprises a chewable, edible and digestible substance. The invention is characterised in that the shape of the object (1) comprises at least two dihedrals (d1, d2) having edges (a1, a2) which essentially extend along the entire length of the object.

Abstract: A composition for use in the treatment of a condition or disorder related to mucosal barrier dysfunction in the gut, the composition comprising activated carbon. The condition may be, for example, pouchitis or proctitis.

Abstract: The following invention relates to a taste enhancer and a method of enhancing taste. The invention relates the use of a cooling enhancing composition which provides cooling enhancement when combined with other cooling compounds.

Abstract: Suggested is a pharmaceutical composition, comprising menthane carboxylic acid-N-(4-methoxy-phenyl)-amide.

Abstract: Provided are compositions, e.g., oral and personal care products, comprising (i) a zinc (amino acid or trialkyl glycine) halide complex, and (ii) cysteine in free or in orally or cosmetically acceptable salt form, together with methods of making and using the same.

Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a local anesthetic in the form of a clear oily solution and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.

Abstract: A structured surfactant system with a very high degree of clarity. The system comprises water and a mixture of at least one surfactant having a HLB (Hydrophilic Lipophilic Balance) value of less than 10, and at least one surfactant having an HLB value of 10 or greater. The structured surfactant system forms multilamellar vesicles and has suspending properties without added electrolytes, carbohydrates, or polymeric thickeners. This makes the structured surfactant system particularly useful in personal care compositions.